Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.
Forge Biologics, Inc. is a contract development and manufacturing organization based in Columbus, Ohio, focused on developing and manufacturing gene therapies and genetic medicines. The company specializes in viral vector gene therapies aimed at treating genetic diseases, including a novel approach combining adeno-associated virus (AAV) with umbilical cord transplants for infantile Krabbe disease, a severe neurodegenerative condition. Founded in 2019, Forge Biologics partners with scientists, healthcare professionals, and biotech and pharmaceutical companies to facilitate the transition of gene therapy programs from preclinical development to clinical and commercial-scale production. By providing end-to-end capabilities, the company aims to accelerate the availability of transformative medicines for patients suffering from rare genetic disorders.
Dren Bio is a biotechnology company with a portfolio of attractive projects focused on powerful protein engineering technologies for the depletion of cells, protein aggregates, and other disease-causing agents. It is a holding company business model aimed at creating value with multiple projects as stand-alone assets.
Garuda Therapeutics is a biotechnology company focused on creating off-the-shelf hematopoietic stem cell therapies aimed at treating various severe and life-threatening conditions. The company specializes in addressing blood, bone marrow, immune, and metabolic diseases. By leveraging expertise in innovative research methods, including the use of zebrafish, mice, and human-induced pluripotent stem cells, Garuda analyzes novel genes and mechanisms vital for blood formation. This approach enables the development of mechanism-based therapies designed to improve patient outcomes.
Biomea Fusion is a preclinical-stage biopharmaceutical company dedicated to advancing precision medicine for cancer treatment. The company's focus is on the discovery and development of irreversible small molecule drugs that target specific genetic alterations associated with tumor growth. Its lead product candidate, BMF-219, is designed as a potent and selective irreversible inhibitor of menin, a key transcriptional regulator involved in oncogenic signaling across various cancers. Biomea Fusion aims to expedite the development of these innovative therapies to provide highly effective treatment options for patients with genetically defined cancers.
Reneo Pharmaceuticals develops therapies for patients with rare genetic mitochondrial diseases, which impact cellular metabolism and energy production. Founded in 2014 and based in San Diego, California, the company is focused on creating treatments that enhance mitochondrial function, thereby improving muscle health and overall quality of life for affected individuals. Its lead product candidate, REN001, is an oral medication designed to modulate genes essential for energy metabolism and the production of adenosine triphosphate (ATP), the primary energy source for cellular processes. By addressing the underlying metabolic deficiencies in these patients, Reneo aims to prevent muscle injury, weakness, and wasting, ultimately enhancing daily functioning for those with these orphan diseases.
Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.
Elevation Oncology, Inc. is a biotechnology company dedicated to creating precision medicines for patients with genomically defined cancers. Founded in 2019 and headquartered in New York, the company focuses on developing targeted therapies that inhibit specific genetic alterations associated with cancer progression. Its lead candidate, seribantumab, is designed to address tumor growth driven by NRG1 fusions and is currently undergoing clinical evaluation in the Phase 2 CRESTONE study, which includes patients with various tumor types exhibiting this genomic alteration. Through its innovative approach, Elevation Oncology aims to enhance treatment options for individuals with solid tumors linked to specific genetic drivers.
Spruce Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for rare endocrine disorders. Founded in 2014 and based in Daly City, California, the company is primarily focused on its lead candidate, tildacerfont, which is being evaluated in Phase II clinical trials for classic congenital adrenal hyperplasia (CAH) in both adults and children. Tildacerfont aims to be the first non-steroidal treatment that enhances disease control while minimizing the reliance on steroids for managing CAH. Additionally, Spruce Biosciences is exploring tildacerfont's potential applications in treating polycystic ovary syndrome in women. The company has also entered a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications. Through its efforts, Spruce Biosciences seeks to significantly improve the quality of life for patients with rare endocrine disorders who have historically been underserved by medical advancements.
Nuvation Bio Inc., a biopharmaceutical company, focuses on the development of therapies for oncology. Its portfolio includes various oncology programs with multiple drug development candidates. Nuvation Bio Inc.was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. The company was founded in 2018 and is based in New York, New York with an additional office in San Francisco, California.
Ajax Health is a private equity and venture capital firm established in 2017, with its headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in investing across all stages of a company's lifecycle, focusing on innovative medical device companies, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by providing both capital and strategic capabilities to address significant challenges in healthcare. Through its investments, the firm seeks to foster advancements in healthcare technologies and improve patient outcomes.
Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing innovative therapies for patients with significant unmet medical needs. The company is advancing a diverse pipeline that includes treatments for hematological malignancies and solid tumors, as well as liver-directed gene therapies aimed at rare diseases. Poseida is known for its proprietary gene engineering platforms, including the non-viral piggyBac DNA Modification System and the Cas-CLOVER site-specific gene editing system, which facilitate the creation of next-generation cell and gene therapeutics. Additionally, the company's portfolio encompasses CAR-T therapies for cancer and gene therapies targeting rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia. Founded in 2014, Poseida Therapeutics is committed to addressing critical health challenges through its advanced therapeutic solutions.
Ajax Health is a private equity and venture capital firm established in 2017, with its headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in investing across all stages of a company's lifecycle, focusing on innovative medical device companies, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by providing both capital and strategic capabilities to address significant challenges in healthcare. Through its investments, the firm seeks to foster advancements in healthcare technologies and improve patient outcomes.
BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.
Atreca, Inc. is a biopharmaceutical company based in South San Francisco, California, focused on discovering and developing antibody-based immunotherapeutics for various solid tumors. Its lead product candidate, ATRC-101, is a monoclonal antibody currently in clinical development, which demonstrates a unique mechanism of action and targets derived from antibodies identified through Atreca's innovative discovery platform. ATRC-101 has shown in vitro reactivity with a significant majority of cancer samples, including those from ovarian, non-small cell lung, colorectal, and breast cancer patients. Additionally, the company has established a strategic research collaboration with Merck Sharp & Dohme Corp. to identify antigenic targets of select antibodies with potential applications in oncology. Founded in 2010, Atreca aims to advance its therapies to improve treatment options for cancer patients.
Ajax Health is a private equity and venture capital firm established in 2017, with its headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in investing across all stages of a company's lifecycle, focusing on innovative medical device companies, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by providing both capital and strategic capabilities to address significant challenges in healthcare. Through its investments, the firm seeks to foster advancements in healthcare technologies and improve patient outcomes.
Eidos Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California, focused on developing innovative treatments for transthyretin amyloidosis (ATTR), a disease caused by the misfolding of the transthyretin protein. The company is advancing its lead drug candidate, AG10, which is currently in phase 3 clinical trials. AG10 is an orally administered small molecule designed to stabilize the tetrameric form of transthyretin, effectively preventing the molecular processes that lead to the development of ATTR. Founded in 2013, Eidos Therapeutics operates as a subsidiary of BridgeBio Pharma, Inc., which is dedicated to creating genetically targeted therapies to enhance patient outcomes.
Zosano Pharma Corporation is a clinical stage biopharmaceutical company based in Fremont, California, established in 2006. The company specializes in developing therapeutics for migraine sufferers through its innovative intracutaneous microneedle delivery system. Its primary product candidate, Qtrypta (M207), is a proprietary formulation of zolmitriptan aimed at treating migraines. Zosano Pharma is committed to discovering and developing drug candidates that meet significant unmet medical needs and have strong commercialization potential.
Avrobio is a clinical-stage gene therapy company based in Cambridge, Massachusetts, focused on developing ex vivo lentiviral gene therapies aimed at treating rare diseases with a single-dose approach. The company utilizes hematopoietic stem cells collected from patients, which are modified using a lentiviral vector to insert functional copies of defective genes associated with specific diseases. Avrobio's lead product candidate, AVR-RD-01, is currently in Phase II clinical trials for Fabry disease. Additionally, the company's pipeline includes AVR-RD-02, which has completed preclinical trials for type 1 Gaucher disease; AVR-RD-03, in preclinical development for Pompe disease; and AVR-RD-04, which has also completed preclinical studies for cystinosis. Avrobio has established a research collaboration with Magenta Therapeutics to explore targeted antibody-drug conjugates as a conditioning regimen for its lentiviral gene therapies. Founded in 2015, Avrobio aims to leverage advancements in cell and gene therapies to provide potential cures for serious and debilitating conditions.
ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.
GTx, Inc. is a company of pioneering and driven individuals who are delivering better medicines with new science through established pathways.
BridgeBio is a biotechnology company dedicated to the discovery, development, and delivery of medicines for genetic diseases. The company has a diverse pipeline of 20 development programs, which range from early discovery to late-stage clinical trials. Among its notable candidates are BBP-265, an oral small molecule targeting transthyretin amyloidosis currently in Phase 3 trials, and infigratinib, a selective tyrosine kinase inhibitor aimed at treating FGFR-driven cancers and achondroplasia. Additionally, BridgeBio is developing BBP-631, a preclinical gene therapy for congenital adrenal hyperplasia, and BBP-454, a program focused on small molecule inhibitors for KRAS-driven cancers. The company collaborates with several prestigious institutions, including Stanford University and Johns Hopkins University, to enhance its research and development efforts. Founded in 2015 and headquartered in Palo Alto, California, BridgeBio aims to accelerate the development of therapies for Mendelian diseases, genetic dermatology, and oncology.
VYNE Therapeutics is a late-stage biopharmaceutical company that specializes in the development and commercialization of serlopitant, a treatment for pruritus associated with various dermatologic conditions, including atopic dermatitis, psoriasis, and prurigo nodularis. The company aims to address a significant unmet medical need, as there are currently no approved therapies in the United States that specifically target pruritus in these conditions. In addition to its focus on dermatologic applications, VYNE is also investigating serlopitant for refractory chronic cough, a persistent cough that lasts more than eight weeks despite treatment. Serlopitant acts as a selective small molecule inhibitor of the neurokinin 1 receptor and is administered as an oral tablet once daily. The company has completed Phase II clinical trials for pruritus related to various conditions and is planning to advance into Phase III trials for prurigo nodularis, anticipating further data to support its clinical development. VYNE Therapeutics is headquartered in Redwood City, California, and was established in 2011.
Promentis Pharmaceuticals, Inc. is a biopharmaceutical company based in Milwaukee, Wisconsin, established in 2006. The company specializes in developing therapies for neuropsychiatric disorders, with a focus on addressing glutamatergic imbalance and oxidative stress. Promentis is known for its lead compound, SXC-2023, which targets System xc- to treat multiple conditions, including impulse control disorders and obsessive-compulsive disorder. In addition to SXC-2023, Promentis is also working on other compounds aimed at restoring glutamatergic neurotransmission, which is crucial for improving cortical function and managing various psychiatric disorders, including schizophrenia.
Ajax Health is a private equity and venture capital firm established in 2017, with its headquarters in Menlo Park, California, and an additional office in New York City. The firm specializes in investing across all stages of a company's lifecycle, focusing on innovative medical device companies, healthcare services, digital health, biotechnology, and healthcare IT. Ajax Health aims to accelerate medical innovation by providing both capital and strategic capabilities to address significant challenges in healthcare. Through its investments, the firm seeks to foster advancements in healthcare technologies and improve patient outcomes.
Prolacta Bioscience Inc. specializes in developing and producing human milk-based nutritional products tailored for premature and critically ill infants in neonatal intensive care units (NICUs). Founded in 1999 and headquartered in Duarte, California, the company offers a range of products including human milk fortifiers, caloric fortifiers, standardized human milk, and ready-to-feed formulas. Prolacta is notable for being the first company to provide a human milk fortifier made entirely from human milk, known as Prolact+ H2MF. The company operates a pharmaceutical-grade processing facility that employs patented methods to ensure the quality and safety of its products, which address the immunological and nutritional needs of vulnerable infants. Prolacta Bioscience is committed to enhancing the quality of life for critically ill infants through innovative research and specialized formulations.
Verona Pharma is a clinical-stage biopharmaceutical company headquartered in London, United Kingdom, that specializes in developing therapies for chronic respiratory diseases with significant unmet medical needs. The company's lead product candidate, ensifentrine, is an inhaled dual inhibitor of phosphodiesterase 3 and 4, functioning as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), and alternative delivery methods, including a dry powder inhaler and a pressurized metered-dose inhaler, are also being explored. In addition to COPD, Verona Pharma aims to develop ensifentrine for other respiratory conditions such as cystic fibrosis and asthma. Founded in 2005, the company is committed to improving the health and quality of life for individuals affected by these challenging diseases.
F2G Ltd develops novel therapies to treat fungal diseases. It primarily focuses on developing an F3 series of anti-mold compound, which is an antifungal agent. The company offers orotomides that are antifungal agents against Aspergillus and other filamentous molds. F2G Ltd was formerly known as Functional Fungal Genomics Ltd and changed its name to F2G Ltd in July 1999. F2G Ltd was founded in 1998 and is based in Manchester, United Kingdom.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative dermatologic and immunologic therapies. Founded by the team behind Vicept Therapeutics, Aclaris is dedicated to addressing significant unmet medical needs in dermatology and immunology, particularly in areas lacking FDA-approved treatments. The company operates in two main segments: therapeutics and contract research. The therapeutics segment focuses on creating novel drug candidates for immuno-inflammatory diseases, while the contract research segment generates revenue by providing laboratory services. Aclaris's pipeline includes drug candidates such as Zunsemetinib, an oral MK2 inhibitor, aiming to fill critical treatment gaps in the healthcare landscape.
Miramar Labs, founded in 2006 and based in Sunnyvale, California, specializes in developing medical devices for aesthetic applications. The company's primary product, the miraDry System, offers a non-invasive solution for adults suffering from primary axillary hyperhidrosis, which is excessive sweating in the underarm area. This innovative system employs microwave energy to selectively target and permanently eliminate sweat and odor glands, providing a long-lasting, non-surgical treatment option that enhances the confidence and quality of life for its users. The miraDry System is specifically designed for underarm treatment and is not applicable for hyperhidrosis in other areas of the body, such as the hands and feet.
PowerVision, Inc. is a company that specializes in the development of innovative accommodating intraocular lens technology aimed at restoring vision for individuals affected by presbyopia and cataracts. Based in Belmont, California, PowerVision's flagship product, the FluidVision intraocular lens, utilizes a small amount of fluid within the lens to mimic the natural functioning of a healthy eye, allowing users to dynamically adjust their focus for clear vision at all distances. This technology is designed to address the vision needs of millions, particularly the elderly, who suffer from cataracts and the age-related loss of near vision associated with presbyopia. By offering a solution that potentially eliminates the need for glasses or other forms of vision correction, PowerVision aims to significantly improve the quality of life for those facing these common age-related vision challenges. The company was incorporated in 2002 and was acquired by Alcon Laboratories, Inc. in March 2019.
Zavante Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing innovative medicines for the treatment of diseases affecting hospitalized patients. The company's primary product in development is ZOLYD, an investigational injectable antibiotic aimed at addressing serious and life-threatening infections caused by multi-drug resistant gram-negative and gram-positive bacteria. Founded in 2013, Zavante Therapeutics operates as a subsidiary of Nabriva Therapeutics plc, with a commitment to improving patient outcomes in critical care settings.
Spirox, Inc. is a medical device company headquartered in Menlo Park, California, focused on improving the quality of life for patients suffering from nasal obstruction due to nasal valve collapse. Formerly known as Nasoform LLC, the company develops innovative solutions to address this common but often undertreated condition. Their flagship product, the LATERA absorbable nasal implant, aims to provide effective treatment for nasal valve collapse, enhancing nasal airflow and overall patient comfort. Founded in 2011, Spirox operates as a subsidiary of Entellus Medical, Inc. and is actively involved in completing product development, seeking U.S. marketing authorization, and initiating commercialization efforts.
Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
Spirox, Inc. is a medical device company headquartered in Menlo Park, California, focused on improving the quality of life for patients suffering from nasal obstruction due to nasal valve collapse. Formerly known as Nasoform LLC, the company develops innovative solutions to address this common but often undertreated condition. Their flagship product, the LATERA absorbable nasal implant, aims to provide effective treatment for nasal valve collapse, enhancing nasal airflow and overall patient comfort. Founded in 2011, Spirox operates as a subsidiary of Entellus Medical, Inc. and is actively involved in completing product development, seeking U.S. marketing authorization, and initiating commercialization efforts.
Cynapsus is a pharmaceutical company based in Toronto, Ontario, established in 2004, that focuses on developing innovative treatments for Parkinson's disease. The company specializes in creating a non-injectable sublingual thin film formulation, APL-130277, designed for the on-demand management of OFF episodes, which are debilitating periods when symptoms of Parkinson's worsen. Cynapsus has successfully completed a Phase two clinical trial for this product candidate, which utilizes apomorphine hydrochloride as its active ingredient. The company's work aims to enhance the quality of life for individuals living with Parkinson's disease by providing an alternative to traditional injectable therapies.
Aimmune Therapeutics is a company operating in the United States biotechnology industry. Its main focus is in the development of product candidates to combat peanut and other food allergies. The company's therapeutic approach, which is referred to as Characterized Oral Desensitization Immunotherapy, is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols, and support services.
Cidara Therapeutics is a biotechnology company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative anti-infective therapies. The company's lead product candidate, rezafungin acetate, is an antifungal agent from the echinocandin class designed to treat and prevent serious invasive fungal infections, such as candidemia and invasive candidiasis, which carry high mortality rates. In addition to its antifungal efforts, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating viral infections, including influenza, RSV, HIV, and coronaviruses. Founded in 2012, Cidara Therapeutics has positioned itself as a key player in addressing life-threatening illnesses, particularly those that pose challenges due to immune system deficiencies.
Agile Therapeutics, Inc. is a women's healthcare company dedicated to developing and commercializing prescription contraceptive products. The company’s lead product, Twirla, is a once-weekly transdermal contraceptive patch that delivers a low dose of levonorgestrel and ethinyl estradiol. Agile Therapeutics is also advancing a pipeline of related products, including various line extensions of Twirla and additional transdermal contraceptive options. These include regimens designed to extend menstrual cycles or provide shorter and lighter periods, as well as a progestin-only patch intended for women who cannot or prefer not to use estrogen. Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics aims to address the unmet healthcare needs of women through innovative contraceptive solutions.
Private Equity Round in 2015
LensAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, that specializes in the design, development, and marketing of an advanced femtosecond laser system for cataract treatment. Founded in 2004, LensAR aims to enhance refractive cataract surgery through innovative laser and 3D imaging technologies. Its flagship product, the LENSAR Laser System, incorporates proprietary technologies that assist surgeons in achieving precise visual outcomes while optimizing procedure efficiency and reproducibility. The system features advanced imaging capabilities, simplified procedure planning, and precision tools, along with associated consumable components, including a disposable patient interface device and procedure license. Through its offerings, LensAR seeks to improve the overall visual outcomes for patients undergoing cataract surgery.
Syros Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead candidates, SY-1425, a selective retinoic acid receptor alpha agonist currently undergoing Phase II trials for specific patients with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I trials for select advanced solid tumors. Syros employs a proprietary platform that integrates assay technologies, bioinformatics, and biological insights to map gene regulatory circuits and modulate gene expression, positioning itself as a leader in gene control research. Additionally, Syros has established collaborations, including a target discovery agreement with Incyte Corporation focused on myeloproliferative neoplasms, and a licensing agreement with TMRC Co. Ltd. for tamibarotene's development and commercialization. Founded in 2011, Syros Pharmaceuticals aims to address significant unmet medical needs in oncology and beyond.
Miramar Labs, founded in 2006 and based in Sunnyvale, California, specializes in developing medical devices for aesthetic applications. The company's primary product, the miraDry System, offers a non-invasive solution for adults suffering from primary axillary hyperhidrosis, which is excessive sweating in the underarm area. This innovative system employs microwave energy to selectively target and permanently eliminate sweat and odor glands, providing a long-lasting, non-surgical treatment option that enhances the confidence and quality of life for its users. The miraDry System is specifically designed for underarm treatment and is not applicable for hyperhidrosis in other areas of the body, such as the hands and feet.
Dermira is a specialty biopharmaceutical company focused on bringing innovative and differentiated products to dermatologists and their patients. Dermira’s portfolio of five product candidates targets significant market opportunities.
It was founded in 2010 and headquartered in Menlo Park, California.
Paratek Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapies for life-threatening infectious diseases and other serious health conditions. The company’s lead products include NUZYRA, an oral and intravenous broad-spectrum antibiotic effective against community-acquired bacterial pneumonia and acute bacterial skin infections, and SEYSARA, a tetracycline antibiotic for treating moderate to severe acne vulgaris. Paratek’s research is anchored in tetracycline chemistry and biology, and the company actively collaborates with partners such as Zai Lab and Allergan, as well as academic institutions like Tufts University. Additionally, Paratek engages in cooperative research with the U.S. Army Medical Research Institute of Infectious Diseases to explore treatment options against infectious agents. Founded in 1996, Paratek continues to expand its focus on addressing severe diseases, including research into multiple sclerosis and systemic inflammatory conditions.
Cidara Therapeutics is a biotechnology company based in San Diego, California, dedicated to the discovery, development, and commercialization of innovative anti-infective therapies. The company's lead product candidate, rezafungin acetate, is an antifungal agent from the echinocandin class designed to treat and prevent serious invasive fungal infections, such as candidemia and invasive candidiasis, which carry high mortality rates. In addition to its antifungal efforts, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates aimed at preventing and treating viral infections, including influenza, RSV, HIV, and coronaviruses. Founded in 2012, Cidara Therapeutics has positioned itself as a key player in addressing life-threatening illnesses, particularly those that pose challenges due to immune system deficiencies.
PowerVision, Inc. is a company that specializes in the development of innovative accommodating intraocular lens technology aimed at restoring vision for individuals affected by presbyopia and cataracts. Based in Belmont, California, PowerVision's flagship product, the FluidVision intraocular lens, utilizes a small amount of fluid within the lens to mimic the natural functioning of a healthy eye, allowing users to dynamically adjust their focus for clear vision at all distances. This technology is designed to address the vision needs of millions, particularly the elderly, who suffer from cataracts and the age-related loss of near vision associated with presbyopia. By offering a solution that potentially eliminates the need for glasses or other forms of vision correction, PowerVision aims to significantly improve the quality of life for those facing these common age-related vision challenges. The company was incorporated in 2002 and was acquired by Alcon Laboratories, Inc. in March 2019.
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc.; strategic partnership agreement with Illumina, Inc.; research collaboration agreement with Veracyte, Inc.; and strategic partnership agreement with Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Ltd. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Loxo Oncology, Inc. is a subsidiary of Eli Lilly and Company.
Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss.The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
Seragon Pharmaceuticals, Inc., headquartered in Irvine, California, is a research-based biopharmaceutical company dedicated to improving human and animal health through innovative science. Seragon Pharmaceuticals is committed to applying cutting-edge scientific and technological advancements to the fields of metabolism, gene therapy and bioinformatics. From the research end to consumer products and clinical applications, Seragon strives to bring people access to the most significant breakthroughs in medicine. For more information, please visit www.seragon.com
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
Loxo Oncology, Inc., a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer. The company’s preclinical programs include LOXO-195, a drug candidate in preclinical development to address predicted acquired resistance mechanisms; RET inhibitor that optimizes potency for rearranged during transfection (RET) fusion proteins, mutations, and anticipated mechanisms of acquired resistance; and FGFR inhibitor that enables potently inhibiting FGFR isoforms comprising four isoforms with tyrosine kinase domains. It has a drug discovery collaboration agreement with Array BioPharma, Inc.; strategic partnership agreement with Illumina, Inc.; research collaboration agreement with Veracyte, Inc.; and strategic partnership agreement with Amoy Diagnostics Co., Ltd. and PREMIA Holdings (HK) Ltd. Loxo Oncology, Inc. was founded in 2013 and is headquartered in Stamford, Connecticut. Loxo Oncology, Inc. is a subsidiary of Eli Lilly and Company.
LensAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, that specializes in the design, development, and marketing of an advanced femtosecond laser system for cataract treatment. Founded in 2004, LensAR aims to enhance refractive cataract surgery through innovative laser and 3D imaging technologies. Its flagship product, the LENSAR Laser System, incorporates proprietary technologies that assist surgeons in achieving precise visual outcomes while optimizing procedure efficiency and reproducibility. The system features advanced imaging capabilities, simplified procedure planning, and precision tools, along with associated consumable components, including a disposable patient interface device and procedure license. Through its offerings, LensAR seeks to improve the overall visual outcomes for patients undergoing cataract surgery.
Private Equity Round in 2013
LensAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, that specializes in the design, development, and marketing of an advanced femtosecond laser system for cataract treatment. Founded in 2004, LensAR aims to enhance refractive cataract surgery through innovative laser and 3D imaging technologies. Its flagship product, the LENSAR Laser System, incorporates proprietary technologies that assist surgeons in achieving precise visual outcomes while optimizing procedure efficiency and reproducibility. The system features advanced imaging capabilities, simplified procedure planning, and precision tools, along with associated consumable components, including a disposable patient interface device and procedure license. Through its offerings, LensAR seeks to improve the overall visual outcomes for patients undergoing cataract surgery.
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
Private Equity Round in 2013
TRIA Beauty, Inc. specializes in the development and marketing of light-based medical devices designed for consumer use in skincare and beauty treatments. The company offers a range of products, including a hand-held diode laser for hair removal, a blue light device targeting acne-causing bacteria, a fractional non-ablative laser for skin rejuvenation, and an eye wrinkle correcting laser. These devices provide effective solutions that allow users to achieve professional results at home. TRIA Beauty's products are available through its e-commerce platform and various retail channels, including television and physical stores, across multiple regions, including the United States, Japan, and several European countries. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty was previously known as SpectraGenics, Inc. before rebranding in 2008.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix. Headquartered in Redwood City, California, Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner. The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman.
Ambit Biosciences is a privately-held biopharmaceutical company dedicated to the discovery and development of small molecule kinase inhibitors aimed at treating cancer, inflammatory diseases, and other conditions. The company's lead compound, AC220, is a selective, orally bioavailable FMS-like tyrosine kinase-3 (FLT3) inhibitor currently undergoing clinical trials for patients with relapsed or refractory acute myeloid leukemia (AML). Ambit is collaborating with Astellas Pharma Inc. to jointly develop and commercialize FLT3 kinase inhibitors across various indications. The clinical pipeline also includes AC480, a pan-HER inhibitor, and AC430, an oral JAK2 inhibitor. In addition, Ambit has several preclinical candidates, including CEP-32496, a BRAF inhibitor that has been licensed to Cephalon. Through its innovative research, Ambit aims to improve treatment outcomes for patients suffering from cancer.
Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.
TRIA Beauty, Inc. specializes in the development and marketing of light-based medical devices designed for consumer use in skincare and beauty treatments. The company offers a range of products, including a hand-held diode laser for hair removal, a blue light device targeting acne-causing bacteria, a fractional non-ablative laser for skin rejuvenation, and an eye wrinkle correcting laser. These devices provide effective solutions that allow users to achieve professional results at home. TRIA Beauty's products are available through its e-commerce platform and various retail channels, including television and physical stores, across multiple regions, including the United States, Japan, and several European countries. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty was previously known as SpectraGenics, Inc. before rebranding in 2008.
Intercept Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases in North America and Europe. Its lead product, Ocaliva, is a farnesoid X receptor agonist approved for the treatment of primary biliary cholangitis (PBC) in adults, often used in conjunction with ursodeoxycholic acid. The company is also advancing Ocaliva for other conditions, including nonalcoholic steatohepatitis (NASH), alongside several additional product candidates at various stages of clinical and preclinical development. Intercept has established licensing agreements for Ocaliva with Sumitomo Dainippon Pharma for markets in Japan and China, and with Aralez Pharmaceuticals for the development of bezafibrate in the United States. The company employs an internal commercial team, contract sales organizations, and third-party distributors to market its products. Founded in 2002, Intercept Pharmaceuticals is headquartered in New York, New York.
Agile Therapeutics, Inc. is a women's healthcare company dedicated to developing and commercializing prescription contraceptive products. The company’s lead product, Twirla, is a once-weekly transdermal contraceptive patch that delivers a low dose of levonorgestrel and ethinyl estradiol. Agile Therapeutics is also advancing a pipeline of related products, including various line extensions of Twirla and additional transdermal contraceptive options. These include regimens designed to extend menstrual cycles or provide shorter and lighter periods, as well as a progestin-only patch intended for women who cannot or prefer not to use estrogen. Founded in 1997 and headquartered in Princeton, New Jersey, Agile Therapeutics aims to address the unmet healthcare needs of women through innovative contraceptive solutions.
PreCision Dermatology is a fully-integrated dermatology company with a mission to deliver innovative therapies to doctors and patients that demonstrably improve the care of skin. PreCision Dermatology is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities.
Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
LensAR, Inc. is a commercial-stage medical device company based in Orlando, Florida, that specializes in the design, development, and marketing of an advanced femtosecond laser system for cataract treatment. Founded in 2004, LensAR aims to enhance refractive cataract surgery through innovative laser and 3D imaging technologies. Its flagship product, the LENSAR Laser System, incorporates proprietary technologies that assist surgeons in achieving precise visual outcomes while optimizing procedure efficiency and reproducibility. The system features advanced imaging capabilities, simplified procedure planning, and precision tools, along with associated consumable components, including a disposable patient interface device and procedure license. Through its offerings, LensAR seeks to improve the overall visual outcomes for patients undergoing cataract surgery.
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics aimed at treating immune deficiencies and infectious diseases in the United States. The company's product portfolio includes BIVIGAM and ASCENIV, both intravenous immune globulin products indicated for primary humoral immunodeficiency, as well as Nabi-HB, which treats acute exposure to Hepatitis B. ADMA also has a pipeline of therapeutics targeting infections such as S. pneumonia. To support its production, ADMA operates FDA-licensed source plasma collection facilities, known as ADMA BioCenters, which supply plasma for its products. The company distributes its offerings through independent distributors, sales agents, and specialty pharmacies. Founded in 2004 and headquartered in Ramsey, New Jersey, ADMA Biologics is dedicated to serving niche patient populations, particularly those who are immune-compromised due to underlying conditions or medical treatments.
CeNeRx BioPharma, Inc., a drug development company, engages in identifying, developing, and commercializing therapeutics to treat diseases related to neurotransmitters and the nervous system. The company's product pipeline includes Tyrima, CX2614, and CX009, which are reversible inhibitors of monoamine oxidase- A that are used for the treatment of mood, anxiety, and somatic disorders. It focuses on developing therapeutics to treat diseases related to neurotransmitters, including anxiety, bipolar disorder, dementia, depression, epilepsy, neuropathic pain, schizophrenia, and Parkinson's and Alzheimer's diseases. The company was founded in 2005 and is based in Cary, North Carolina.
Roka Bioscience specializes in the development of rapid and accurate molecular assays and instrument systems aimed at the food safety industry. The company's latest innovation, the Atlas System, introduces advanced molecular rapid pathogen testing, which enhances laboratory efficiency through automation and user-friendly design. By focusing on innovative testing solutions, Roka Bioscience aims to assist food manufacturers in minimizing risks, safeguarding their brands, and addressing the growing demands for testing in the sector.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
T2 Biosystems, Inc. is an in vitro diagnostics company based in Lexington, Massachusetts, specializing in the development of diagnostic products for pathogen detection and biomarker analysis. Utilizing its proprietary T2 Magnetic Resonance technology, the company offers a range of diagnostic solutions that can analyze various unpurified patient samples such as blood, saliva, and urine without extensive sample preparation. Key products include the T2Dx Instrument, which detects pathogens linked to sepsis and Lyme disease, and specific panels like the T2Candida Panel for identifying Candida species, the T2Bacteria Panel for detecting bacterial pathogens, and the T2SARS-CoV-2 Panel for COVID-19 testing. T2 Biosystems is also developing additional panels for multi-drug resistant pathogens and Lyme disease strains. The company collaborates with Canon U.S. Life Sciences and Allergan Sales for advancing its diagnostic offerings. Founded in 2006, T2 Biosystems aims to enhance diagnostic accuracy and speed in medical settings.
Pharmaron Beijing Co., Ltd. is a leading provider of research and development services for the pharmaceutical industry, serving clients across North America, Europe, Asia, and beyond. Established in 2004 and headquartered in Beijing, the company operates through four main segments: Laboratory Services, Manufacturing and Controls Services, Clinical Development, and Others. Pharmaron offers a comprehensive range of services, including laboratory chemistry, drug metabolism and pharmacokinetics, in vitro biology, safety assessments, process development, and formulation manufacturing. Additionally, the company specializes in clinical research, regulatory bioanalysis, and contract research services. By investing in its workforce and facilities, Pharmaron has positioned itself to meet the evolving needs of the life sciences sector, thereby facilitating the development and manufacturing of pharmaceutical products globally.
TRIA Beauty, Inc. specializes in the development and marketing of light-based medical devices designed for consumer use in skincare and beauty treatments. The company offers a range of products, including a hand-held diode laser for hair removal, a blue light device targeting acne-causing bacteria, a fractional non-ablative laser for skin rejuvenation, and an eye wrinkle correcting laser. These devices provide effective solutions that allow users to achieve professional results at home. TRIA Beauty's products are available through its e-commerce platform and various retail channels, including television and physical stores, across multiple regions, including the United States, Japan, and several European countries. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty was previously known as SpectraGenics, Inc. before rebranding in 2008.
NextWave Pharmaceuticals is a Cupertino, California-based pharmaceutical company that specializes in the development and commercialization of innovative drug delivery technologies. The company primarily focuses on creating once-daily liquid medications for the treatment of attention deficit/hyperactivity disorder (ADHD). By leveraging its proprietary technology, NextWave aims to provide effective treatment options that enhance patient compliance and address disorders related to the central nervous system.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
Zeltiq (pronounced Zel ′teek) Aesthetics, founded in 2005, is a science-based medical device company dedicated to the development of non-invasive procedures for the reduction of unwanted fat tissue. The Zeltiq approach utilizes a patented method called Cryolipolysis™ (the use of precisely controlled cooling to remove fat) that is designed to target only fat cells and not harm the skin or other tissue. The Zeltiq device is cleared by the FDA in the Unites States for various applications related to skin cooling during dermatologic treatments.
Aragon Pharmaceuticals is a discovery-stage small molecule company dedicated to developing therapeutics for hormone-resistant cancers, particularly focusing on prostate and breast cancer. The company specializes in anti-endocrine therapies that target the biology of these cancers. Its research emphasizes nuclear receptor biology, medicinal chemistry, and drug discovery, with the goal of identifying and developing selective androgen receptor degraders for prostate cancer and selective estrogen receptor degraders for estrogen-sensitive breast cancer.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
TransEnterix, Inc. is a medical device company that focuses on the research, development, and sale of robotic systems designed to enhance minimally invasive surgery. Its primary products include the Senhance System, a multi-port robotic surgery system that utilizes multiple robotic arms for instrument control and camera operation, and the SurgiBot System, a single-port robotically enhanced laparoscopic surgical platform. These systems enable surgeons to perform complex procedures, such as gallbladder removal, with minimal scarring. TransEnterix markets its products directly and through distributors in various regions, including Europe, the United States, Japan, and Taiwan. Founded in 2006, the company is headquartered in Morrisville, North Carolina.
Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.
Bridge Pharmaceuticals is a drug development research organization based in Gaithersburg, Maryland. It provides toxicology and pharmacology services to support investigational new drug applications on a global scale.
TRIA Beauty, Inc. specializes in the development and marketing of light-based medical devices designed for consumer use in skincare and beauty treatments. The company offers a range of products, including a hand-held diode laser for hair removal, a blue light device targeting acne-causing bacteria, a fractional non-ablative laser for skin rejuvenation, and an eye wrinkle correcting laser. These devices provide effective solutions that allow users to achieve professional results at home. TRIA Beauty's products are available through its e-commerce platform and various retail channels, including television and physical stores, across multiple regions, including the United States, Japan, and several European countries. Founded in 2003 and headquartered in Dublin, California, TRIA Beauty was previously known as SpectraGenics, Inc. before rebranding in 2008.
Esperion Therapeutics, Inc. is a pharmaceutical company focused on developing and commercializing oral therapies for patients with elevated low-density lipoprotein cholesterol (LDL-C). Founded in 2008 and headquartered in Ann Arbor, Michigan, the company specializes in non-statin medications aimed at treating conditions such as atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia. Its primary product candidates include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which are designed to improve cholesterol management. Esperion also explores novel treatment approaches, including HDL Therapy, based on its understanding of high-density lipoprotein function. The company collaborates with Daiichi Sankyo Europe GmbH to enhance its research and development efforts.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
Sanofi-Topaz (formerly Topaz Pharmaceuticals) develops and manufactures pharmaceutical products for children’s health issues. It provides various drugs for the treatment of head lice, acne, and infections, as well as vaccines against childhood diseases. Sanofi-Topaz was founded in 2005 and is headquartered in Horsham, Pennsylvania.
Sanofi-Topaz (formerly Topaz Pharmaceuticals) develops and manufactures pharmaceutical products for children’s health issues. It provides various drugs for the treatment of head lice, acne, and infections, as well as vaccines against childhood diseases. Sanofi-Topaz was founded in 2005 and is headquartered in Horsham, Pennsylvania.
Paratek Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing and commercializing therapies for life-threatening infectious diseases and other serious health conditions. The company’s lead products include NUZYRA, an oral and intravenous broad-spectrum antibiotic effective against community-acquired bacterial pneumonia and acute bacterial skin infections, and SEYSARA, a tetracycline antibiotic for treating moderate to severe acne vulgaris. Paratek’s research is anchored in tetracycline chemistry and biology, and the company actively collaborates with partners such as Zai Lab and Allergan, as well as academic institutions like Tufts University. Additionally, Paratek engages in cooperative research with the U.S. Army Medical Research Institute of Infectious Diseases to explore treatment options against infectious agents. Founded in 1996, Paratek continues to expand its focus on addressing severe diseases, including research into multiple sclerosis and systemic inflammatory conditions.
Xanodyne Pharmaceuticals, Inc. operates as an integrated specialty pharmaceutical company that offers developing and commercializing products in women’s healthcare and pain management in the United States.The company was formerly known as Xanodyne Pharmacal, Inc. and changed the name to Xanodyne Pharmaceuticals, Inc. in February, 2004. Xanodyne Pharmaceuticals, Inc. was incorporated in 2000 and is based in Newport, Kentucky.
Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.
BioRelix, Inc., a biopharmaceutical company, engages in the discovery and development of anti-biotic drug candidates for the treatment of infectious diseases in the United States. It develops a portfolio of riboswitch-based therapeutic agents to overcome the lethal and devastating causes of bacterial infections. The company was founded in 2005 and is based in New Haven, Connecticut.
Bioenvision a biopharmaceutical company, engages in the acquisition, development, and marketing of compounds and technologies primarily for the treatment of cancer. Its lead products include Evoltra (clofarabine) which has marketing approval in both the European Union and United States for the treatment of pediatric relapsed or refractory acute lymphoblastic leukemia and Modrenal (trilostane), which has marketing approval in the United Kingdom for the treatment of post-menopausal breast cancer following relapse to initial hormone therapy.
Natural Dentist
Series B in 2007
As of February 23, 2010, The Natural Dentist, Inc. was acquired by Revive Personal Products Company. The company manufactures oral care products in the United States. It offers mouth rinses and toothpastes through stores and online retailers, as well as through phone. The company was formerly known as Woodstock Natural Products Inc and changed its name to The Natural Dentist, Inc. in 2005. The Natural Dentist, Inc. was founded in 1995 and is based in Medford, Massachusetts.
Sirion Therapeutics is a Tampa, FL-based company dedicated to the development and commercialization of innovative ophthalmic products.
Cempra is a clinical-stage pharmaceutical company dedicated to discovering and developing innovative medicines aimed at curing bacterial infections and enhancing the quality of life for individuals with chronic illnesses. The company focuses on creating antibiotics specifically designed to treat multi-drug resistant bacterial infections, offering advanced treatment options for patients both in hospitals and within the community. Cempra is currently advancing the development of its lead product, CEM-101, while simultaneously investing in new technologies to discover the next generation of antibiotics. Through this dual approach, Cempra aims to address the growing challenge of drug resistance in bacterial infections.